Aim of this study is to evaluate the background and the effectiveness of anti-influenza agents for influenza inpatients. We collected information about inpatients diagnosed with influenza from November 2016 to April 2019 in our hospital from medical charts. In results, 188 inpatients (2016/2017: 58 patients, 2017/2018: 54 patients, 2018/2019: 76 patients) had been diagnosed with influenza. The medications prescribed comprised oseltamivir (50 patients), peramivir (95), zanamivir (two), laninamivir (five), and baloxavir marboxil (34). Two patients received no medication. One hundred and eighty patients had risk factors for influenza complications. Duration of fever after the prescription of anti-influenza agents (2.51±2.20 days), length of hospital stay (18.3±22.3 days), and mortality rate (16/188 patients) showed no significant differences between the groups when classified by anti-influenza agents. In conclusion, consistent with the previous reports, patients prescribed baloxavir marboxil showed no significant differences between the patients prescribed other anti-influenza agents in terms of duration of fever, length of hospitalization, or mortality rate.